On April 7, 2016 Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, reported the acceptance of an abstract for an oral plenary session presentation relating to its Phase 1 clinical development program for entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in New Orleans, Louisiana (Press release, Ignyta, APR 7, 2016, View Source [SID:1234510530]). The company also announced the acceptance of three other abstracts for poster presentations at the meeting, relating to entrectinib, the company’s RXDX-107 product candidate, and a novel diagnostic statistical method to assess RNA expression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored that the Scientific Program Committee has selected our entrectinib Phase 1 data update abstract for an oral presentation, as well as three additional abstracts for poster presentations," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We look forward to sharing data from each of these abstracts in this prestigious forum, and to discussing the data and our future plans with key scientific and clinical experts."

Details of the presentations are as follows:

Oral presentation:

Date/time: Sunday, April 17, 2016, 5:12 PM – 5:30 PM, Central time
Title:
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements – updated phase 1 results. (Abstract number CT007)
Presenter: Alexander Drilon, M.D., Memorial Sloan Kettering Cancer Center

Poster presentations:

Date/time: Monday, April 18, 2016, 1:00 PM – 5:00 PM, Central time
Title:
Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers. (Abstract number 2136)

Date/time: Wednesday, April 20, 2016, 8:00 AM – 12:00 PM, Central time
Title:
RXDX-107 exhibits multiple mechanisms of intracellular delivery and results in extensive drug-induced interstrand crosslinks in solid tumor preclinical models. (Abstract number 4780)

Date/time: Wednesday, April 20, 2016, 8:00 AM – 12:00 PM, Central time
Title:
A novel, statistical-based method to determine RNA expression by next-generation sequencing in clinical FFPE samples. (Abstract number 5274)